GlassScriptPhysician profile
Douglas M Shepard
NPI 1700804721
$408.74
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.64 · 2020: $191 · 2021: $122 · 2022: $70.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electronic Waveform Lab, INC. | $82.84 | 2019-2021 | |
| Novo Nordisk INC | $57.84 | 2020 | |
| Lilly USA, LLC | $55.84 | 2020-2022 | |
| Glaxosmithkline, LLC. | $39.82 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.11 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.70 | 2021 | |
| Daiichi Sankyo INC. | $21.37 | 2020 | |
| Optinose US, INC. | $18.29 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.91 | 2022 | |
| Eisai INC. | $17.12 | 2021 | |
| Endo Pharmaceuticals INC. | $16.09 | 2020 | |
| Abbott Laboratories | $13.57 | 2022 | |
| Sanofi Pasteur INC. | $13.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.